Agilon Health, Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2025. Agilon Health operates a Medicare-centric, globally capitated line of business, partnering with community-based physician groups to manage the total healthcare needs of attributed patients. As of year-end, the platform served approximately 511,000 Medicare Advantage (MA) members and 114,000 beneficiaries through CMS Accountable Care Organization (ACO) models. The company operates 30 geographies with 28 anchor physician groups.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $5,932.6 | $6,060.5 | (2.1%) |
| Medical Services Expense | $5,977.9 | $5,842.5 | +2.3% |
| Gross Profit (Loss) | $(160.0) | $4.8 | Turned to Loss |
| Medical Margin | $(56.6) | $205.2 | Significant Decline |
| Net Loss | $(391.3) | $(260.1) | Widened |
| Adjusted EBITDA Loss | $(296.2) | $(154.2) | Widened |
| Cash and Cash Equivalents | $173.7 | $188.2 | (7.7%) |
| Marketable Securities | $111.4 | $211.7 | (47.4%) |
| Total Debt Outstanding | $35.0 | $35.0 | Flat |
Note: Medical Margin is a non-GAAP measure defined as medical services revenue less medical services expense. The company recorded a $36.1 million impairment charge in 2025, primarily related to goodwill and intangible assets.
Material Changes vs. Prior Period
- Profitability Deterioration: The company shifted from a gross profit of $4.8 million in 2024 to a gross loss of $160.0 million in 2025. Medical margin collapsed from $205.2 million to a negative $56.6 million.
- Revenue Decline: Total revenue decreased 2% to $5.93 billion, driven by a 2% decline in average MA membership (due to partnership exits in 2024) and lower risk adjustment revenue.
- Expense Increase: Medical services expense increased 2% to $5.98 billion, primarily due to a 5% increase in average medical services expense per member driven by elevated cost trends.
- Impairments: Impairment charges surged 903% to $36.1 million, including a $24.1 million goodwill impairment and a $12.0 million intangible asset impairment.
- Membership: MA members decreased 3% to 511,000, while CMS ACO Models beneficiaries decreased 13% to 114,000.
Guidance, Outlook, Risks, and Unusual Items
- NYSE Listing Compliance: The company received notice on November 5, 2025, of non-compliance with NYSE listing standards due to a share price below $1.00 for 30 consecutive days. Agilon plans to seek stockholder approval for a reverse stock split (ratio of 1-for-5 to 1-for-25) at a special meeting on March 17, 2026, to regain compliance.
- Leadership Transition: Steven Sell resigned as CEO, President, and board member on July 29, 2025. The company is currently operating under interim leadership while searching for a permanent CEO.
- Debt Restructuring: On February 10, 2026, the company amended its Credit Facility, extending the maturity date to February 18, 2028. The amendment includes a requirement to maintain $50.0 million in total cash and conditions certain payments on achieving positive EBITDA for two consecutive trailing four-quarter periods.
- Regulatory Risks: The company faces significant risks related to CMS risk adjustment audits (RADV), potential changes to the ACO REACH Model (transitioning to the LEAD Model in 2027), and federal healthcare funding levels.
- Legal Proceedings: The company is subject to multiple securities class action lawsuits and stockholder derivative lawsuits alleging violations of securities laws related to financial guidance and data management. Discovery is ongoing.
Key Facts for Investor Verification
- Reverse Stock Split Approval: Verify the outcome of the March 17, 2026, special meeting regarding the reverse stock split and subsequent share price performance to ensure NYSE compliance.
- Medical Cost Trends: Monitor the sustainability of the 5% increase in per-member medical costs and the company's ability to improve medical margin in 2026.
- CEO Succession: Confirm the appointment of a permanent Chief Executive Officer and the impact on strategic execution.
- Litigation Exposure: Track the status of the consolidated securities litigation and derivative suits, as outcomes could result in significant financial liability.
- Cash Burn Rate: Assess the company's liquidity position given the negative operating cash flow of $105.8 million in 2025 and the requirement to maintain $50 million in cash under the new credit agreement terms.